TradersLink
$APRESep 10, 2026, 8:00 AM ETAI processed

APRE to Present at H.C. Wainwright Conference; Webcast Sept. 14

AI Summary

Aprea Therapeutics (NASDAQ: APRE) said CEO Oren Gilad will present at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14–16, with a webcast available from 4:30 PM ET on Sept. 14 and management available for one-on-one investor meetings. The company reiterated its lead clinical-stage programs—APR-1051 (oral WEE1 inhibitor) and ATRN-119 (ATR inhibitor)—both in development for solid tumors.

Positives

  • CEO to present at a major investor conference (H.C. Wainwright) Sept. 14–16
  • Webcast of the presentation available Sept. 14 at 4:30 PM ET for broad investor access
  • Company highlighted lead clinical-stage programs APR-1051 and ATRN-119 in solid tumors

Negatives

  • Press release does not include any new clinical or financial data
  • No specific data readout or milestone was announced in connection with the presentation
  • Investors must attend the webcast or meetings to hear any material updates